A Clinical Observation of 1565nm Non-ablative Fractional Laser in the Treatment of Androgenic Alopecia
NCT ID: NCT05827991
Last Updated: 2023-04-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
75 participants
INTERVENTIONAL
2022-03-01
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
2. Studies have shown that phototherapy can effectively improve androgenic alopecia, alopecia areata, and hair loss after chemotherapy, and promote hair growth. At the same time, phototherapy can also be adjusted by adjusting the expression of reductase genes and vascular endothelial growth factor genes, as well as some endogenous epidermal growth factors, such as fibroblast growth factor and insulin-like growth factor, are also upregulated, which can stimulate hair growth.
3.1565 nm non-ablative fractional laser has the effects of inhibiting sebaceous gland secretion of oil, regulating collagen metabolism, and delaying changes in scalp collagen after hair loss. Previous studies have confirmed that 1565 nm non-ablative fractional laser therapy for alopecia areata has a good effect. Its possible mechanisms include increasing local blood flow, stimulating growth factors and cytokines during hair growth. At the same time, in order to achieve low energy, safe, and effective treatment without the need for hair cutting, the investigators had for the first time improved the 1565 nm non non-ablative fractional laser treatment tool, removing the original sapphire crystal cooling contact. This improvement can make the treatment head fully fit the scalp, and the excitation beam acts vertically on the treatment area, reducing energy attenuation.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of an Non-ablative Fractional 1565nm vs. an Ablative 2940-nm Fractional Er Laser for the Treatment of Androgenetic Alopecia
NCT06218498
1565nm Non-ablative Fractional Laser Treat Alopecia Areata
NCT05744505
Role of Minoxidil in Alopecia Areata Transepidermal Drug Delivery of Minoxidil Via Either Fractional Carbon Dioxide Laser or Microneedling Versus Its Topical Nanoparticles Preparation for Treatment of Alopecia Areata
NCT05587257
Laser Assisted Delivery of Minoxidil in Androgenetic Alopecia
NCT03852992
Fractional Laser Versus Radiofrequency in Androgenetic Alopecia
NCT05435625
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1565nm Non-ablative Fractional Laser
1565nm Non-ablative Fractional Laser
1565nm Non-ablative Fractional Laser
1565nm Non-ablative Fractional Laser is used for treatment once every 2 weeks, a total of 10 times. 1565nm Non-ablative Fractional Laser uses square and rectangular light spots, and the size is adjusted according to the treatment area, which is about 8-16mm, 250-300spot, 10J/cm2.
Minoxidil
Minoxidil for external use
5% minoxidil external use
The method of use of 5% minoxidil tincture is for topical use on the scalp, 1 ml per time, 2 times per day.
1565nm Non-ablative Fractional Laser combined with Minoxidil for external use
1565nm Non-ablative Fractional Laser combined with Minoxidil for external use
1565nm Non-ablative Fractional Laser combined with 5% minoxidil
The two treatment mentioned above
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
1565nm Non-ablative Fractional Laser
1565nm Non-ablative Fractional Laser is used for treatment once every 2 weeks, a total of 10 times. 1565nm Non-ablative Fractional Laser uses square and rectangular light spots, and the size is adjusted according to the treatment area, which is about 8-16mm, 250-300spot, 10J/cm2.
5% minoxidil external use
The method of use of 5% minoxidil tincture is for topical use on the scalp, 1 ml per time, 2 times per day.
1565nm Non-ablative Fractional Laser combined with 5% minoxidil
The two treatment mentioned above
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Clinical diagnosis of androgenic alopecia The diagnosis was based on the diagnostic criteria for androgenic alopecia in Clinical Dermatology, edited by Zhao Bian;
3. The patient agrees to participate in this trial and signs an informed consent form;
4. The scalp is free of bleeding, ulceration, infection, and other conditions that affect the visual field of laser surgery.
Exclusion Criteria
2. Those who undergo local scalp treatment within 3 months, including topical drugs, medical cosmetic treatment, etc;
3. Combined with severe damage to important organs such as heart, liver, kidney, and brain;
4. Symptomatic alopecia caused by other diseases, such as lupus erythematosus alopecia and folliculitis alopecia;
5. Scar constitution;
6. Patients with skin malignant tumors or precancerous lesions;
7. Pregnant or nursing;
8. Recent skin infections (such as viruses and bacteria);
9. Those who cannot persist in treatment and follow-up.
18 Years
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Xijing Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dermatology Derpartment of Xijing Hospital
Xi'an, Shaanxi, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
XijingH-PF-KY20222044-F-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.